Finch Therapeutics Group, Inc. (FNCHQ): auditor change — Finch Therapeutics dismisses Deloitte, appoints Wolf & Company as new auditor effective May 12, 2023

Finch Therapeutics Group, Inc.

Audit Committee approved dismissal of Deloitte and engagement of Wolf & Company, effective May 12, 2023.
Decision driven by goal of reducing ongoing costs related to annual audit.
Deloitte's reports for 2021 and 2022 contained no adverse opinion except a going concern explanatory paragraph.
Material weakness in internal controls as of Dec 31, 2019 was remediated as of Dec 31, 2021.
No disagreements or reportable events with Deloitte during 2021, 2022, and through May 8, 2023.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Finch Therapeutics Group, Inc. engaged Wolf & Company, P.C. as its auditor.

Action: engagement
Auditor: Wolf & Company, P.C.

Exact text from the filing

Also on May 8, 2023, the Audit Committee approved the engagement, effective May 12, 2023, of Wolf & Company, P.C. (“Wolf”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Finch Therapeutics Group, Inc. dismissed Deloitte & Touche LLP as its auditor.

Action: dismissal
Auditor: Deloitte & Touche LLP
Successor: Wolf & Company, P.C.

Exact text from the filing

On May 8, 2023, the Audit Committee of the Board of Directors (the “Audit Committee”) of Finch Therapeutics Group, Inc. (the “Company”) approved the dismissal of Deloitte & Touche LLP (“Deloitte”) as the Company’s independent registered public accounting firm, effective May 12, 2023.

View on SEC.gov

Browse all auditor changes →

Finch Therapeutics Group, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-021205

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.